CEL-SCI Corporation, a biopharmaceutical company based in Colorado, has made a significant stride in its efforts to commercialize its investigational cancer immunotherapy, Multikine. The company announced on November 20, 2026, that Multikine has been granted official designation under the Saudi Food and Drug Authority's (SFDA) New Accelerator Program for Drugs in Rare Diseases (NADR). This designation is crucial as it positions Saudi Arabia to potentially become the first commercial market globally for Multikine.
The NADR designation allows CEL-SCI to prepare for a Marketing Authorization Application (MAA) to the SFDA within the next few months. The SFDA's newly enacted guidance provides for priority review, targeting a 160-working-day assessment timeframe, which could enable a commercial launch of Multikine as early as 2027 or 2028, pending approval.
Geert Kersten, CEO of CEL-SCI, expressed optimism about the designation, stating, "The Saudi FDA has demonstrated extraordinary global regulatory leadership by establishing the NADR program. Their forward-looking framework perfectly aligns with Saudi Vision 2030's mandate to bring cutting-edge healthcare innovations to the Kingdom rapidly." He emphasized the importance of this partnership with Amarox, CEL-SCI's in-country regulatory and commercialization partner, in advancing their strategy and supporting Saudi Arabia's goals for biopharmaceutical infrastructure.
Background
CEL-SCI Corporation, trading under the ticker CVM on the NYSE, specializes in biological products, specifically those not classified as diagnostic substances. The company has been actively engaged in developing innovative therapies, particularly for cancer treatment. The recent filing is part of a series of updates, including several 8-K and 4 forms filed throughout 2026.
What the Filing Says
The SEC filing states, "CEL-SCI Corporation... announced that its investigational cancer immunotherapy Multikine has been granted official designation under the Saudi Food and Drug Authority's (SFDA) New Accelerator Program for Drugs in Rare Diseases (NADR)." This achievement highlights the company's ongoing efforts to bring Multikine to market.
Impact
This development is expected to significantly impact CEL-SCI's business strategy and market positioning. The NADR designation not only accelerates the regulatory process but also enhances the company's potential for revenue generation in the Middle East. The partnership with Amarox is particularly pivotal, as it allows CEL-SCI to leverage local expertise and infrastructure, minimizing risks associated with market entry.
What's Next
Following this designation, CEL-SCI and Amarox are preparing to submit a Marketing Authorization Application to the SFDA in the coming months. The filing does not specify further actions beyond this application.
Read Next
Cloudflare's Michelle Zatlyn Sells Over $1.5M in Shares
Zurn Elkay VP LaMotte Jeremy L Reports Stock Sale
XTI Aerospace CEO Jeremy Schneiderman Reports Stock Exchange
Jennifer Salinas acquires 366,529 shares in Cerence Inc.
Mentz Christian acquires 125,979 shares of Cerence Inc.
Cerence CEO Acquires 819,039 Shares in Stock Transaction










